Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial
Vered Stearns(Johns Hopkins University), Paul E. Goss(Harvard University), Pedro Emanuel Rubini Liedke(Massachusetts General Hospital), G. Thomas Budd(Cleveland Clinic), X. Cynthia(Washington University in St. Louis), Kathleen I. Pritchard, Matthew J. Ellis(Guardant (United States)), George W. Sledge(Caris Life Sciences (United States)), Manuela Rabaglio(University Hospital of Bern), James N. Ingle(Mayo Clinic), Aurélie Le Maître(Ontario Institute for Cancer Research), Lois E. Shepherd(Ontario Institute for Cancer Research), Judith‐Anne W. Chapman(Queen's University), Jessica Kundapur(Cancer Care Ontario)
Cited by 43
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k